NCT00955318已完成3 期
Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 58
- 主要终点
- The incidence of adverse events after administration of KW-6500
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of KW-6500 when administered as long-term subcutaneous self-injections in Parkinson's disease patients with motor response complications on levodopa therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have given written informed consent
- •Patients who have Parkinson's disease
- •Patients who have been on a stable regimen of levodopa plus at least one other antiparkinsonian agent and who have OFF state
- •Patients who meet stage 4 or 5 while in the OFF state and stage 0 to 3 while in the ON state on the Modified Hoehn and Yahr Scale
- •Patients who have experienced a 30% or more improvement in UPDRS partⅢ score when tested for responsiveness to levodopa during the baseline period
- •Patients who have at least one OFF state per day
- •Patients who can understand the expression of OFF state, ON state, and dyskinesia
- •Patients or their families have a desire for self-injection of KW-6500
排除标准
- •Patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic, metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system (excluding Parkinson's disease)
- •Patients with orthostatic hypotension
- •Patients with a history of intolerance to morphine or its derivatives, sulfur, sulfur-containing pharmaceutical products, or sulfite
- •Patients with a history of malignant syndrome
- •Patients with a diagnosis of cancer or evidence of continued disease
- •Patients who do not test negative in the direct Coombs' test
- •Pregnant or lactating women, women who are planning to have children, women who test positive in the pregnancy test, or women who cannot adhere to a reliable method of contraception
- •Patients who have received MAO inhibitors except selegiline
- •Patients with a history of mental disease (excluding psychiatric symptoms associated with Parkinson's disease)
- •Patients with a Mini-Mental State Examination (MMSE) score of 23 or less
- •Patients who are taking antipsychotics or central dopamine antagonists (excluding domperidone)
- •Patients who are receiving methyldopa or 5-HT3 receptor antagonists
- •Patients who are receiving reserpine or papaverine
- •Patients who have had a neurosurgical operation for Parkinson's disease
- •Patients who have had transcranial magnetic stimulation
- •Patients with a history of drug or alcohol abuse or dependence
研究组 & 干预措施
KW-6500
Experimental
干预措施: KW-6500 (Drug)
结局指标
主要结局
The incidence of adverse events after administration of KW-6500
时间窗: From first administration of study drug through Study Week 52
Time to expression of the ON state, continuous time of the ON state, raw score change and percent score change in Unified Parkinson's Disease Rating Scale (UPDRS) part III, response ratio, and UPDRS part II score
时间窗: From first administration of study drug through Study Week 52
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
ong-Term Safety Study of KW-6500Parkinson's DiseaseJPRN-jRCT2080220819Kyowa Hakko Kirin Co., Ltd.
未知
3 期
Extended Long-Term Safety Study of KW-6500 (6500-005)Parkinson's DiseaseJPRN-jRCT2080220981Kyowa Hakko Kirin Co., Ltd.
未知
3 期
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)Parkinson's DiseaseJPRN-jRCT2080220980Kyowa Hakko Kirin Co., Ltd.20
已完成
3 期
Extended Long-Term Safety Study of KW-6500Parkinson's DiseaseNCT01063621Kyowa Kirin Co., Ltd.27
未知
3 期
ong-Term Safety Study of KW-6002 (6002-010)Parkinson's DiseaseJPRN-jRCT2080220821Kyowa Hakko Kirin Co., Ltd.150